PDL BioPharma (PDLI) Receiving Somewhat Positive Media Coverage, Report Finds

Headlines about PDL BioPharma (NASDAQ:PDLI) have been trending somewhat positive on Friday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PDL BioPharma earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.4722205421893 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s rankings:

PDLI stock opened at $2.47 on Friday. The firm has a market capitalization of $367.56 million, a PE ratio of 3.92 and a beta of 0.31. The company has a current ratio of 10.03, a quick ratio of 9.75 and a debt-to-equity ratio of 0.14. PDL BioPharma has a 12 month low of $2.15 and a 12 month high of $3.55.

PDL BioPharma (NASDAQ:PDLI) last released its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The business had revenue of $38.52 million for the quarter. PDL BioPharma had a net margin of 33.57% and a return on equity of 11.76%. research analysts expect that PDL BioPharma will post 0.22 EPS for the current fiscal year.

Several research firms have weighed in on PDLI. BidaskClub raised shares of PDL BioPharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research raised shares of PDL BioPharma from a “sell” rating to a “hold” rating in a research report on Tuesday, June 19th. Cowen reissued a “hold” rating and set a $2.50 target price on shares of PDL BioPharma in a research report on Thursday, June 14th. Finally, TheStreet raised shares of PDL BioPharma from a “d+” rating to a “c-” rating in a research report on Friday, March 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.33.

About PDL BioPharma

PDL BioPharma, Inc acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices.

Insider Buying and Selling by Quarter for PDL BioPharma (NASDAQ:PDLI)

Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply